Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors.

C Thomsen, V Bruno, F Nicoletti, M Marinozzi and R Pellicciari
Molecular Pharmacology July 1996, 50 (1) 6-9;
C Thomsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V Bruno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Nicoletti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Marinozzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Pellicciari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 50 no. 1 6-9
PubMed 
8700119

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Published online July 1, 1996.


Author Information

  1. C Thomsen,
  2. V Bruno,
  3. F Nicoletti,
  4. M Marinozzi and
  5. R Pellicciari
  1. Department of Molecular Pharmacology, Novo Nordisk A/S, Malov, Denmark. cht@novo.dk

    Statistics from Altmetric.com

    Article usage

    Article usage: January 2000 to May 2022

    AbstractFullPdf
    Jan 2000100
    May 2000100
    Oct 2000100
    Apr 2001200
    May 2001100
    Aug 2001700
    Oct 2001200
    Jan 2002100
    May 2002100
    Mar 2003100
    May 2003100
    Jul 2003400
    Aug 2003600
    Sep 2003100
    Oct 2003700
    Nov 2003800
    Dec 2003400
    Jan 2004600
    Feb 2004400
    Mar 2004500
    Apr 2004300
    May 2004300
    Jun 2004700
    Jul 20041000
    Aug 2004500
    Sep 2004200
    Oct 2004400
    Nov 2004300
    Dec 2004300
    Jan 2005900
    Feb 2005200
    Mar 2005800
    May 2005200
    Jun 2005200
    Jul 2005100
    Aug 2005103
    Oct 2005100
    Nov 2005101
    Dec 2005101
    Jan 2006101
    Feb 2006202
    Mar 2006301
    May 2006001
    Jul 2006100
    Aug 2006100
    Sep 2006100
    Oct 2006201
    Nov 2006100
    Dec 2006100
    Jan 2007103
    Feb 2007101
    Mar 2007101
    Apr 2007300
    May 2007100
    Jul 2007100
    Aug 2007300
    Sep 2007303
    Oct 2007102
    Nov 2007400
    Dec 2007102
    Jan 2008203
    Feb 2008001
    Mar 2008301
    Apr 2008301
    May 2008200
    Jun 2008100
    Jul 2008301
    Sep 2008200
    Oct 2008301
    Nov 2008201
    Dec 2008100
    Jan 2009103
    Feb 2009201
    Mar 2009402
    Apr 2009001
    May 2009201
    Jun 2009101
    Jul 2009201
    Sep 2009700
    Oct 2009600
    Nov 2009803
    Dec 2009601
    Jan 2010500
    Feb 2010400
    Mar 2010302
    Apr 2010200
    May 2010701
    Jun 2010400
    Jul 2010600
    Aug 2010401
    Sep 2010201
    Oct 2010702
    Nov 2010200
    Dec 2010400
    Jan 2011800
    Feb 2011300
    Mar 2011600
    Apr 2011102
    May 2011802
    Jun 2011900
    Jul 2011900
    Aug 2011701
    Sep 20111102
    Oct 2011700
    Nov 20111101
    Dec 2011902
    Jan 2012800
    Feb 2012200
    Mar 2012500
    Apr 20121300
    May 2012800
    Jun 2012700
    Jul 2012900
    Aug 2012400
    Sep 2012400
    Oct 2012500
    Nov 2012201
    Dec 2012701
    Jan 20131500
    Feb 2013701
    Mar 20131101
    Apr 20131602
    May 2013301
    Jun 2013302
    Jul 2013500
    Aug 2013900
    Sep 2013901
    Oct 20131101
    Nov 2013501
    Dec 2013300
    Jan 2014500
    Feb 2014500
    Mar 2014500
    Apr 2014800
    May 2014400
    Jul 2014601
    Aug 2014600
    Sep 2014200
    Oct 2014400
    Nov 2014600
    Dec 2014800
    Jan 2015502
    Feb 2015600
    Mar 20151200
    Apr 2015500
    May 2015500
    Jun 20151101
    Jul 20151400
    Aug 2015500
    Sep 2015700
    Oct 2015100
    Nov 2015700
    Dec 2015302
    Jan 2016301
    Feb 2016700
    Mar 20161101
    Apr 2016302
    May 2016100
    Jun 2016300
    Jul 2016500
    Aug 2016500
    Sep 2016501
    Oct 2016101
    Nov 2016300
    Dec 2016100
    Jan 2017200
    Feb 2017100
    Mar 2017100
    Apr 2017501
    May 2017400
    Jun 2017400
    Jul 2017600
    Aug 20171100
    Sep 2017300
    Oct 20171000
    Nov 2017900
    Dec 2017600
    Jan 20181100
    Feb 2018500
    Mar 2018600
    Apr 2018801
    May 2018300
    Jun 20181100
    Jul 2018100
    Aug 2018100
    Sep 2018400
    Oct 2018300
    Nov 2018300
    Jan 2019100
    Feb 2019301
    Mar 2019300
    Apr 2019100
    May 2019400
    Jun 2019502
    Jul 2019400
    Aug 2019200
    Sep 2019800
    Oct 20191000
    Nov 2019800
    Dec 2019400
    Jan 2020100
    Feb 2020400
    Mar 2020800
    Apr 2020200
    May 2020800
    Jun 2020302
    Jul 2020100
    Aug 2020200
    Sep 2020600
    Oct 2020900
    Nov 2020300
    Dec 2020400
    Jan 2021900
    Feb 20211000
    Mar 2021600
    Apr 2021800
    May 20213200
    Jun 2021700
    Jul 20211600
    Aug 20211100
    Sep 2021300
    Oct 20211103
    Nov 20211300
    Dec 2021700
    Jan 20221500
    Feb 2022500
    Mar 2022300
    Apr 2022703
    May 2022300

    PreviousNext
    Back to top

    In this issue

    Molecular Pharmacology
    Vol. 50, Issue 1
    1 Jul 1996
    • Table of Contents
    • Table of Contents (PDF)
    • Index by author
    • Back Matter (PDF)
    • Editorial Board (PDF)
    • Front Matter (PDF)
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Molecular Pharmacology article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors.
    (Your Name) has forwarded a page to you from Molecular Pharmacology
    (Your Name) thought you would be interested in this article in Molecular Pharmacology.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Abstract

    (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors.

    C Thomsen, V Bruno, F Nicoletti, M Marinozzi and R Pellicciari
    Molecular Pharmacology July 1, 1996, 50 (1) 6-9;

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Abstract

    (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors.

    C Thomsen, V Bruno, F Nicoletti, M Marinozzi and R Pellicciari
    Molecular Pharmacology July 1, 1996, 50 (1) 6-9;
    del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
    • Info & Metrics
    • eLetters
    • PDF

    Related Articles

    Cited By...

    Similar Articles

    Advertisement
    • Home
    • Alerts
    Facebook   Twitter   LinkedIn   RSS

    Navigate

    • Current Issue
    • Fast Forward by date
    • Fast Forward by section
    • Latest Articles
    • Archive
    • Search for Articles
    • Feedback
    • ASPET

    More Information

    • About Molecular Pharmacology
    • Editorial Board
    • Instructions to Authors
    • Submit a Manuscript
    • Customized Alerts
    • RSS Feeds
    • Subscriptions
    • Permissions
    • Terms & Conditions of Use

    ASPET's Other Journals

    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    ISSN 1521-0111 (Online)

    Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics